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Small GTPases regulate many key cellular processes and their role in human disease validates many
proteins in this class as desirable targets for therapeutic intervention. Reliable recombinant production of
GTPases, often in the active GTP loaded state, is a prerequisite for the prosecution of drug discovery
efforts. The preparation of these active forms can be complex and often constricts the supply to the
reagent intensive techniques used in structure base drug discovery. We have established a fully auto-
mated, multidimensional protein puriﬁcation strategy for the parallel production of the catalytic G-do-
mains of KRas, Rac1 and RalB GTPases in the active form. This method incorporates a four step
chromatography puriﬁcation with TEV protease-mediated afﬁnity tag cleavage and a conditioning step
that achieves the activation of the GTPase by exchanging GDP for the non-hydrolyzable GTP analogue
GMPPnP. We also demonstrate that an automated method is efﬁcient at loading of KRas with mantGDP
for application in a SOS1 catalysed ﬂuorescent nucleotide exchange assay. In comparison to more con-
ventional manual workﬂows the automated method offers marked advantages in method run time and
operator workload. This reduces the bottleneck in protein production while generating products that are
highly puriﬁed and effectively loaded with nucleotide analogues.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cellular processes rely on small GTPases for the regulation of
diverse, key signalling cascades and networks. Signal transduction
relies on the activation of these GTPases when the bound nucleo-
tide is swapped from GDP to the more abundant GTP through
interaction with Guanine Nucleotide Exchange Factors (GEFs) [1,2].
The small GTPase KRas is the most frequently mutated gene in
cancer and is a critical driver and negative prognostic factor for
major presentations including colorectal, pancreatic and non small
cell lung cancer [3]. Rac1 is often implicated in cancer progression,
promoting angiogenesis and metastasis [4]. Similarly, the Ral
GTPases promote tumorigenesis with RalB emerging as a particular
driver of invasion and metastasis [5]. As a consequence, the small
GTPases are established as strongly validated targets fory).
Inc. This is an open access article utherapeutic intervention.
Historically, efforts to target GTPases with small molecules have
proved extremely difﬁcult with several declaring these proteins to
be undruggable. However, persistence on these high value targets
has led to recent encouraging progress, including the direct tar-
geting of mutant KRas [6]. A series of small molecules have been
characterized that directly bind KRas to inhibit SOS1 catalysed
nucleotide exchange in vitro [7,8]. Other small molecules covalently
interacts with the KRas G12C mutant and showmodulation of KRas
G12C in a cellular setting by blocking nucleotide exchange and
trapping the KRas in the inactive GDP form [9]. Additionally, some
cyclic peptides have been reported to affect KRas, blocking protein-
protein interactions with downstream effectors [10].
As a consequence of this high level of target validation in dis-
ease, and encouraging signs of tractability, the small GTPases are
once again the subject of intensifying drug discovery efforts. These
programs often require signiﬁcant amounts of puriﬁed recombi-
nant proteins to prosecute their programs, and often this includesnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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forms.
Protein production can become an early bottleneck in the drug
discovery pipeline and continual, diverse efforts seek to increase
efﬁciency and minimize constraints [11]. Laboratory scale protein
production must routinely generate multi-milligram quantities of
highly puriﬁed targets for NMR, protein crystallography and other
material intensive techniques. This can be a time consuming and
labor intensive process. Recently released FPLC puriﬁcation systems
provide easier access to multidimensional chromatography that
can link sequential puriﬁcation steps to provide an automated
process requiring much less operator intervention [12e14]. The
capacity of the most advanced systems allows for parallel puriﬁ-
cation of multiple proteins in multidimensional conﬁgurations of-
fering signiﬁcant enhancements in the process throughput.
We have developed a new expression vector with an N-terminal
double His8 afﬁnity tag that is highly efﬁcient in the production of
recombinant GTPases. The GTPases are puriﬁed by four FPLC steps
interspersed with afﬁnity tag cleavage by Tobacco Etch Virus pro-
tease and the exchange of GDP to alternative nucleotides, thus
producing highly puriﬁed active or modiﬁed GTPases. A compari-
son of this automated method with a more conventional manual
FPLC workﬂow demonstrates effective protein production with a
substantial reduction in run times and workload.
2. Material and methods
2.1. Creation of the pBDDP-SPR3 expression vector and cloning of
GTPases
In order to satisfy the technical requirements of downstream
applications, a novel expression vector was designed that affords
recombinant protein expression with an N-terminal “double His8”
afﬁnity tag [15] that includes two repeat octa-histidine motifs
separated by a ﬂexible 28mer linker. (More extensive histidine tags
have proven essential for stable metal afﬁnity immobilization in
techniques such as surface plasmon resonance (SPR) [16].) The tag
includes an ENLYFQG sequence to allow removal on cleavage by
Tobacco Etch Virus (TEV) protease (Fig. 1a). The cassette sequence,
including a bespoke multiple cloning site, was gene synthesized
(Genewiz Inc) and cloned into the NcoI and XhoI sites of pET28a
(Novagen) (Fig. 1b) to create pBDDP-SPR3. Three cDNAs encoding
the G-domains of human KRas 4B (1e169), Rac1 (2e177) and RalB
(12e186) were synthesized with codon optimisation for E. coli
expression and each cloned to the BamHI and XhoI sites of pBDDP-
SPR3 to generate three expression constructs. Correct insertions of
the tag-MCS insert to pET28a and the GTPase cDNAs to pBDDP-
SPR3 were conﬁrmed by DNA sequencing.
2.2. Expression of the CDC25 GEF domain of SOS1 and G-domains of
KRas 4B, Rac1 and RalB in pBDDP-SPR3
Plasmids were transformed into the BL21 (DE3) pLysS strain of
E. coli (Merck Millipore) and the transformed cells were cultured
overnight at 37 C in Luria Bertani broth supplemented with 30 mg/
ml kanamycin sulfate (Melford Laboratories Ltd). A volume of 20 ml
this overnight starter culture was used to inoculate each of 6  1 L
of Luria Bertani broth supplemented with 30 mg/ml kanamycin
sulfate. When the OD600 reached approximately 0.8, protein
expression was induced by the addition of IPTG to 0.5 mM and
expression was allowed to proceed for 16 h at 18 C. Cells were
harvested by centrifugation at 4000 rpm for 15 min. Cell pellets
were resuspended in 50 ml lysis buffer (50 mM Tris HCl pH 7.5,
300 mM NaCl, 100 mg ml1 PMSF) and snap frozen in liquid ni-
trogen prior to storage at 80 C.2.3. Small scale validation the soluble expression
In order to conﬁrm successful soluble expression prior to large
scale puriﬁcation, culture samples were collected immediately
prior to IPTG induction and at the time of harvesting. A 1 ml sample
of culture were harvested by centrifugation and resuspended in
100 ml of TBS buffer supplemented with 1 ml of endonuclease
(BaseMuncher, Expedion). In order to achieve ideal loading con-
centrations for SDS-PAGE, the correct cell sample volume (in mi-
croliters) was determined as 8.5÷OD600. Total cell protein was
applied directly to SDS-PAGE to visualize over-expression of the
target.
In addition, a 40 ml volume of culture was centrifuged at
4000 rpm for 15min and the pellet resuspended in 300 ml of 50%
TBS buffer, 50% Bugbuster® (Merck Millipore) and 2 ml of Base-
Muncher endonuclease (Expedion). Lysis was achieved by repeated
freeze thaw cycles and the lysate was clariﬁed in a microcentrifuge
at 13,000 rpm for 10 min. The clariﬁed lysate was applied to a spin
column containing 100 ml of Cobalt-NTA (CoNTA) resin (Agarose
Bead Technologies). Protein was applied to the resin and washed
four times with 500 ml of TBS supplemented with 10 mM imidazole
and the washed beads were ﬁnally resuspended in 70 ml of TBS.
Immobilized proteinwas visualized by directly applying 10 ml of the
CoNTA beads to SDS-PAGE.
2.4. Puriﬁcation of H8-H8-SOS1 564-1049
H8-H8-SOS1 564e1049 was puriﬁed by immobilized metal af-
ﬁnity chromatography (IMAC) on 5 ml HisTrap FF crude column
equilibrated in Buffer A (50 mM TrisHCl pH7.5, 300 mM NaCl,
10 mM Imidazole). The column was washed with Buffer A sup-
plemented with 30 mM imidazole and the protein was eluted by a
two phase linear gradient between IMAC A and IMAC B (50 mM
TrisHCl pH7.5, 300 mM NaCl, 1M Imidazole), applying 4%e50%
IMAC Buffer B over 10 column volumes (50 ml) and 50%e100%
IMAC Buffer B over 5 column volumes (25 ml). SOS1 was further
puriﬁed on a size exclusion chromatography (SEC) 26/60 S75
Superdex Prep Grade column in Buffer D (20 mM TrisHCl pH7.5,
100 mM NaCl).
2.5. Puriﬁcation of GTPases
Cell pellets from 6 L of culture were thawed in a 35 C water
bath, lysed by ultra-sonication and the lysates clariﬁed by centri-
fugation at 20,000 rpm for 1 h. Protein puriﬁcation and condi-
tioning was performed on an €AKTA AVANT 25 FPLC operated by
Unicorn 7 software (GE Healthcare). The conﬁguration of the €AKTA
systemwas as per the manufacturer's standard with the addition of
a second sample inlet valve, to increase input capacity, and a loop
valve to store and deliver reagents for nucleotide exchange.
Each GTPase was puriﬁed by a sequence of chromatography
steps (all columns from GE Healthcare). Initial capture was ach-
ieved by IMAC on 5 ml HisTrap FF crude columns using the same
buffers and strategy described for the puriﬁcation of H8-H8-SOS1
564e1049. Eluted protein was collected as either 2 ml fractions in
the fraction collector or in a 50 ml tube via the outlet valve,
depending on the protocol used. GTPases were buffer exchanged
via a 26/10 desalting (DS) column into Buffer C (20 mM Tris HCl
pH7.5, 300 mM NaCl, 3 mM DTT). The double His8 tag was then
removed by incubationwith H8-TEV S219V protease [17] (produced
as previously described [18]) at a 1:50 w/w ratio for a minimum of
6 h at 4 C. Proteins were then applied to a size exclusion chro-
matography (SEC) 26/60 S75 Superdex Prep Grade column in Buffer
D (20 mM Tris HCl pH7.5, 100 mM NaCl) with a 5 ml HisTrap FF
crude column attached at the SEC column outlet to trap any
Fig. 1. The pBDDP-SPR3 expression vector. (A) General structure of the recombinant protein produced from pBDDP-SPR3 showing two N-terminal His8 tags separated by a 28
amino acid linker followed by a TEV cleavage site. (B) The sequence and features of the pBDDP-SPR3 tag and multiple cloning site: This cassette was designed with ﬂanking NcoI and
XhoI sites to allow cloning into pET28a. This resulted in the removal of the entire pET28a tag and MCS region and replacement with the BDDP-SPR3 insert.
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conditioned by a nucleotide exchange reaction, and the proteinwas
separated from excess unbound nucleotide by a 26/10 desalting
column in Buffer E (10 mM Tris HCl pH7.5, 50 mM NaCl, 2 mM
MgCl2).
2.6. Nucleotide exchange
The exchange of GDP (guanosine diphosphate) for the nucleo-
tide analogues was achieved by methods adapted from Scherer
et al. [19]. For the exchange of GDP to GMPPnP (guanosine 50-[b,g-
imido]triphosphate), an appropriate volume (typically 3 ml) of 10
exchange buffer (containing at minimum ﬁve-fold molar excess of
GMPPnP; 2M (NH4)3PO4, 1 mM ZnCl2, 5 mM GMPPnP) was deliv-
ered to the GTPase. This was achieved by either an automated step,
supplying reagent from a reservoir attached to a loop valve, or by
manual addition. Also, 10U per milligram of alkaline phosphatase
agarose (Roche) was included by either pre-positioning in the
collection tube for the SEC output, or by manual addition. GDP to
GMPPnP nucleotide exchange was performed to completion on
incubation for a minimum of 4 h at 4 C.
KRas was loaded with mantGDP by incubating the protein with
a molar excess of nucleotide (800 mM) and 10 mM EDTA for 2 h at
4 C. Reactions were then supplemented with 10 mM MgCl2 and
incubated for a further 1 h at 4 C prior to desalting into Buffer E.
Automation of mantGDP loading was achieved by positioning of a
10 stock solution, of 8 mM mantGDP plus 50 mM EDTA, in a
reservoir attached to position 1 of the loop valve. Similarly, MgCl2
was delivered from a 200 mM stock attached to loop valve position
2.2.7. Workﬂow conﬁgurations
GTPase puriﬁcations were performed either as single runs or as
parallel batches where all three targets were processed in each step
using the Unicorn 7 software “scouting” functionality.
In addition, workﬂows were designated as either “manual” or
“automated”. Manual workﬂow involved conventional practices
where proteins were applied to a single chromatography technique
and puriﬁed material was subsequently collected from the €AKTA
fraction collector by the operator. The protein was then pooled and
prepared for application to the next step in the production pro-
cedure, including manual addition of protease or nucleotide
loading reagents.
Automated workﬂow made use of the Unicorn software's
“method queueing” functionality where all sequential chromatog-
raphy steps can be programmed to run in sequence with no oper-
ator intervention. The desired peaks from automated puriﬁcation
steps were sent to 50 ml tubes via the €AKTA outlet valve. Sample
inlet lines were pre-positioned in these tubes to allow onward
delivery to downstream steps. H8-TEV S219V and alkaline phos-
phatase agarose were pre-positioned in the appropriate interme-
diate tubes during the run setup. Other reagents for nucleotide
exchange buffer were delivered to the pool of protein from a 10 ml
sample loop attached to an €AKTA loop valve.
2.8. HPLC assessment of GMPPnP loading
A 500 ml sample of protein at approximately 50 mM was heated
to 95 C for 2 min to denature the protein and release bound
nucleotide. The precipitated proteinwas removed by centrifugation
Fig. 2. Small Scale expression analysis from pBDDP-SPR3 constructs. GTPases were
expressed in the Bl21 (DE3) pLysS strain of E. coli in Luria Bertani broth supplemented
with 30 mg/ml kanamycin sulfate. A 1 ml sample of cells was collected before induction
and at the time of cell harvesting. This allowed the assessment of total cell protein by
SDS-PAGE, and the visualisation of over-expressed target protein. A 40 ml sample of
expression culture was applied to a small scale CoNTA IMAC puriﬁcation to demon-
strate the presence of soluble his-tagged protein. (As reported by others, CoNTA spin
column puriﬁcation has proved particularly useful in this respect and gives a consis-
tently clear indication of levels and integrity of recombinant proteins [20].) In all three
cases there was signiﬁcant soluble expression of the GTPase allowing progression to
FPLC scale puriﬁcation (H8-H8-KRas 1e169, 24.8 kDa; H8-H8-Rac1-2-177, 26.2 kDa; H8-
H8-RalB, 25.5 kDa).
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HPLC auto-sampler. Analysis was carried out on a Shimadzu HPLC
using a Xselect® C18 CSH 2.5 mm column (4.6 mm  7.5 cm)
(Waters) running at 1.5 ml per minute in a buffer of 100 mM K3PO4
pH6.5, 10 mM tetra-butyl-ammonium-bromide and 7.5% acetoni-
trile. Detection of nucleotide was achieved by monitoring absor-
bance at 254 nm and the nucleotide was identiﬁed with reference
to 100 mM GDP or GMPPnP standards.
2.9. SOS1 catalysed nucleotide exchange of KRas
A ﬂuorescent based nucleotide exchange assay was performed
using mantGDP loaded KRas 1e169. This assay monitors the
quenching of mantGDP ﬂuorescence as it is displaced from KRas by
GTPgS on interaction with the GEF SOS1. KRas 1e169 (mantGDP
loaded) and SOS1 (564e1049) were mixed in a black, 96 well plate
to concentrations of 500 nM and 100 nM respectively and a volume
of 23 ml. Samples were mixed on a shaking platform for 2 min and
baseline ﬂuorescence was established by an Inﬁnite M1000 Pro
ﬂuorimeter (Tecan) (excitation wavelength, 360 nm; emission
wavelength 430 nm). The reactionwas initiated by the addition and
mixing of 2 ml of GTPgS to a ﬁnal concentration of 200 mM. Nucle-
otide exchange was measured by the decrease in emission at
430 nm over a period of 90 min measuring every 60 s.
3. Results
3.1. Validation of expression of soluble human GTPases from
pBDDP-SPR3
As part of a workﬂow optimisation program we decided to
introduce routine small scale analysis of expression cultures prior
to protein puriﬁcation of the batch. In this way we would validate
batches for onward puriﬁcation or discard batches that were un-
satisfactory and inefﬁcient for further work. We determined the
level of recombinant protein by noting the appearance of the target
in expression cultures following IPTG induction, and conﬁrming the
presence of soluble GTPase that could be puriﬁed by IMAC resins.
Cultures were incubated and induced as per our most common
laboratory protocols, and these proved satisfactory for recombinant
expression. A small sample of cells were harvested at the time of
induction (T ¼ 0) and at harvesting (endpoint) and resuspended in
TBS buffer. A simple formula related culture OD600 to the volume of
resuspension buffer to generated a sample that gave an appropriate
concentration of total cell protein on an SDS-PAGE gel. In this way
we could typically ensure a gel lane of well separated bands with a
clear indication of the overexpressed target GTPase. In the vast
majority of expression cultures the G-domains of KRas, Rac1 and
RalB expressedwell in pBDDP-SPR3. In addition an acceptably clean
small scale Co-NTA puriﬁcation conﬁrmed the presence of all three
GTPases as soluble proteins at appropriate molecular weights and
with intact His-tags, thus conﬁrming suitability of the batches for
onward FPLC puriﬁcation (Fig. 2).
3.2. Design of an automated, multidimensional, parallel production
strategy
In order to increase throughput and productivity we devised a
strategy for the parallel, automated production of several activated
GTPases by multi-dimensional chromatography. Puriﬁcation was
achieved using standard enrichment and puriﬁcation approaches,
principally IMAC and SEC. Desalting columns were incorporated to
facilitate buffer exchange. In our hands, these GTPases aggregate
after sufﬁcient exposure to imidazole, resulting in a loss of yield and
quality. Buffer was exchanged immediately after IMAC to ensure noimidazole persisted during the 6 h incubation with TEV protease. A
second buffer exchange was required following nucleotide loading,
as the GMPPnP is applied at signiﬁcant molar excess so the un-
bound nucleotide must be removed from the ﬁnal product and
exchange buffer conditions are not ideal for downstream applica-
tions. Overall, the sequence of the workﬂowwas IMAC->Desalting-
>TEV cleavage (6 h pause)->S75 SEC*->Nucleotide exchange (4 h
pause)->Desalting (panel, Fig. 3). (*SEC had a 5 ml nickel column in
line to trap uncleaved product and TEV protease.)
For tag cleavage, TEV protease was pre-placed in the tube allo-
cated to receive the appropriate desalting column elution peak. To
produce active GTPases the nucleotide was exchanged from GDP to
a GTP analogue as the protein emerges from E. coli in the inactive
GDP bound form. In our workﬂow we incorporated the nucleotide
exchange of GDP with the non-hydrolyzable GMPPnP (or other
required analogue) following elution from the SEC column. Alkaline
phosphatase agarose reagent was pre-placed in the tubes receiving
the material for nucleotide exchange. A 10 exchange buffer, con-
taining the concentrated ammonium sulfate and GMPPnP, was held
apart from the agarose until required. (The high salt concentration
of the 10 buffer eliminated the phosphatase activity and it was
preferable to keep the GMPPnP and phosphatase separate in case
some low level hydrolysis did occur.) A loop valve was added to the
AKTA conﬁguration to hold a reservoir of 10 exchange buffer
stock. Following the completion of the SEC column, a short method
was included in the method queue to deliver 3 ml of 10 exchange
buffer to the protein in the waiting tubes. This material was applied
at a ﬂow rate of 10 ml per minute and this successfully agitated the
phosphatase agarose in the tube to disperse it throughout the
Fig. 3. Multidimensional schematic for parallel GTPase production. An example ﬂow diagram of the multidimensional puriﬁcation conﬁguration on the €AKTA AVANT 25 system
for the parallel puriﬁcation of three active, GMPPnP loaded GTPases. Flow of samples to and from the columns was achieved using tubing connected to sample inlet or outlet valves
respectively. Each puriﬁcation included four column steps and integrated both TEV protease tag cleavage and a nucleotide loading reaction. GTPases were puriﬁed on a dedicated
5 ml HisTrap FF IMAC column followed by a 26/10 desalting column to remove imidazole. H8-TEV S219V protease then cleaved the tag from the GTPases during a 6 h incubation.
Cleaved proteins were puriﬁed further on a 26/10 S75 Superdex Prep Grade Column with a 5 ml HisTrap FF column attached downstream (to capture H8-TEV S219V and any un-
cleaved material). Finally the protein was delivered to an aliquot of alkaline phosphatase agaorse. The 10 nucleotide exchange buffer, containing an excess of GMPPnP, was
delivered to from a reagent reservoir connected to a loop valve. Nucleotide loading was allowed to proceed for 4 h and a ﬁnal 26/10 desalting run removed excess nucleotide and
collected the material in the integrated fraction collector prior to delivery. All intermediate product collection, protease reactions and nucleotide loading was performed in pre-
positioned 50 ml tubes. GE Healthcare Unicorn 7.0 software was programmed with a series of “scouting” runs and “method queues” to automatically schedule all steps in the
production workﬂow running in sequence and without any user intervention.
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were held in two 10 ml sample loops on the loop valve and
appropriate volumes delivered to initiate and stabilise exchange.)
TEV protease, exchange buffer, and nucleotide exchange reagents
were applied at concentrations sufﬁcient to achieve the desired
modiﬁcation of the maximum anticipated protein yield. As there
was some variation in yields between replicate batches, it was not
possible to be precise with ratios but we observed no negative ef-
fects on the product on occasions where the modifying reagents
were in unnecessary excess.
The multi-dimensional ﬂowpath and run scheduling were
established using the method queuing functionality in GE Health-
care's Unicorn software incorporating pauses to allow for tag
cleavage or nucleotide exchange. The parallel puriﬁcation of mul-
tiple GTPases used the Unicorn 7 scouting option, were the pro-
cessing of several samples can be included in the samechromatography method. To prosecute the three production runs,
an integrated multidimensional ﬂow path was established utilising
12 ports of the extended sample inlet valve, 5 ports of the column
selection valve, 9 ports of the outlet valve and the fraction collector
(Fig. 3). All intermediate products were successfully collected in
50 ml tubes via the outlet valve ensuring the appropriate peak was
selected and positioned for onward processing.
In order to restrain the early sample volume, the elution
gradient from the IMAC was steep to compress the volume of that
ﬁrst elution peak and restrain requirements to one SEC column run
per GTPase. However, sample dilution was noted through the run
and it was common to run two ﬁnal desalting columns after
nucleotide exchange to process the entire ﬁnal sample volume.
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system
An example of the set of chromatograms is presented in Fig. 4,
illustrating the puriﬁcation of tag cleaved, activated KRas 1e169. A
robust workﬂowwas achieved following trial and optimisation that
allowed the successful isolation of all the GTPase targets. Proteins
isolated by both automated and manual methods exhibited
mobility on SDS-PAGE consistent with a species cleaved by TEV
protease. Comparison of products from the automated and manual
workﬂows showed comparable levels of purity on coomassie
stained gels. However, using silver stain revealed that the material
from the multidimensional workﬂow appeared to be marginally
more puriﬁed (Fig. 5).
An initial concern was that stringent peak recognition parame-
ters and rigid adherence to injection volumes within runs would
result in a reduced yield from the automated method versus the
manual approach. Surprisingly we routinely encountered the
opposite. As expected the comparative yields from the ﬁrst IMAC
step showed the lowest discrepancy between approaches with
average outputs from both methods approximately equal (n ¼ 3)
(Fig. 6a). However, greater loses are consistently observed with theFig. 4. Puriﬁcation of GTPases. A typical set of chromatograms generated on the multidime
nucleotide loading-Desalting. Prior understanding of the puriﬁcation behaviour of each GTP
peak via the outlet valve and the successful delivery of the product to the next column inmanual method. It would appear that a combination of extended
processing time and the manipulation and transfer of intermediate
products between plasticware results in more attrition than the
automated approach. Marginally, the greatest point of loss is seen
in the yields from the SEC column, possibly as result of increased
protein aggregation following prolonged storage in the fraction
collector or from manual handling. Ultimately, substantial multi-
milligram quantities were obtained by all methods but the auto-
mated approach invariably returned the higher yields with the
enhancement ranging between 8.5% and 16.9% when compared to
the manual workﬂow (Table 1).3.4. Nucleotide loading and SOS1 catalysed nucleotide exchange
GMPPnP status was ascertained by HPLC. Both manual and
automated loading showed complete incorporation of GMPPnP in
all GTPases with a positive GMPPnP peak, at amplitudes consistent
with the analyzed protein concentration, and a complete absence of
any signal for the GDP species (Fig. 7).
The utility of KRas 1e169 loaded withmantGDPwas assessed by
application in a SOS1 dependant ﬂuorescent nucleotide exchange
assay (Fig. 8a). Both methods produced loaded material thatnsional puriﬁcation of KRas 1e169 through IMAC-Desalting-TEV protease cleavage-SEC-
ase allowed methods to be compiled that ensured the collection of the correct elution
the series.
Fig. 5. SDS-PAGE analysis of puriﬁed proteins. A total of approximately 5 mg (5 ml of
1 mg ml1) of each protein was analyzed by SDS-PAGE and demonstrated good levels
of purity and complete removal of the H8-H8- tag. Comparable purity was observed on
coomassie stained gels, more sensitive analysis by silver staining suggested that there
was a slightly reduced presence of minor contaminant species with proteins produced
by the automated method.
Fig. 6. Analysis of protein yields from automatic and manual workﬂows. Average yields for each column step were established for both automated and manual workﬂows by
integrating the elution peak area using the Unicorn 7 evaluation module. Multi-milligram quantities of each GTPase were invariably produced but the automated approach
consistently returned higher yields.
Table 1
A comparison of ﬁnal yields (mg) from each approach revealed an enhancement of
between 8.5% and 16.9% through the use of the automated workﬂow.
Automatic Manual Manual vs Auto
KRas 1e169 48.0 39.9 83.1%
Rac1 2e177 61.4 55.5 90.2%
RalB 12e186 46.9 42.9 91.5%
C.H. Gray et al. / Protein Expression and Puriﬁcation 132 (2017) 75e84 81showed very similar exchange kinetics of SOS1 dependant ex-
change (automated, 1.15 ± 0.032  103 sec1; manual
1.20 ± 0.010  103 sec1) demonstrating that automated prepara-
tion of mantGDP loaded material was suitable for downstream
applications (Fig. 8b).3.5. Evaluation of workﬂow enhancements from the automated
system
Often individual process steps in a manual method will com-
plete outside routine working hours leaving the equipment idle or
extending the incubation times with TEV protease or nucleotide
exchange reagents. This is not the case in the automated method
which has substantial time beneﬁts compared to the manual
approach. We established typical processing times for each work-
ﬂow and demonstrated that the parallel puriﬁcation of the three
GTPases was over 29 h faster using the automated multidimen-
sional method. When comparing the single GTPase run data, the
automated preparation of a one GTPase domain almost 24 h quicker
(Fig. 9). The net result is quicker delivery, increased FPLC
throughput and a fresher protein product delivered to the down-
stream application.4. DiscussionMany research programs, including structure based drug dis-
covery, utilize a lot of protein intensive techniques, such as x-ray
crystallography, nuclear magnetic resonance or isothermal titration
calorimetry. As a consequence it is very easy for protein production
to become a rate limiting factor in the discovery process. Whilst it is
Fig. 7. HPLC analysis of GMPPnP loading. Analysis of the nucleotide content of puriﬁed proteins demonstrated complete exchange for GMPPnP in both manual and automated
processes. A typical comparison of manual versus automatic loading of KRas 1e169 by HPLC demonstrates the sole presence of the GMPPnP species and the complete absence of
GDP, at levels consistent with the concentration of the protein analyzed.
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advisable to monitor bottlenecks and be mindful of opportunities
to reduce or eliminate them. To achieve efﬁciencies in this area we
decided to design a ﬂexible, fully automated system for the parallel
production of multiple activated GTPases.
We developed pBDDP-SPR3 expression vector by replacing the
tag and multiple cloning site of pET28a with our own bespoke
conﬁguration. This encodes for two His8 motifs, a TEV protease
cleavage sequence and a simpliﬁed multiple cloning site, and offers
an easy to use ﬂexible expression vector tailored to our laboratory's
activities. This vector has now been used in the successful over-
expression of scores of proteins in addition to those described in
this paper.
The scheduling of the puriﬁcations on FPLC systems also rep-
resented an opportunity for process optimisation. The FPLCs were
inactive for signiﬁcant amounts of time during the puriﬁcation if
the operator was committed to another task or a process step
completed outside of core working hours. It was clear that a
reduced requirement for frequent manual intervention could
enhance throughput by potentially reducing run times, uplifting
capacity and may also provide the added reproducibility and reli-
ability that can accompany automation. By enhancing the capability
of our AKTA AVANT 25 systems with extra sample inlets and a loop
valve we were able to develop a parallel multidimensional process
for the fully automated production of nucleotide loaded GTPases.
As the overall puriﬁcation sequence between automated and
manual methods was the same, there was no expectation that
moving to a multidimensional system would result in an
improvement in protein purity. Comparison of products on coo-
massie stained gels suggested that purity levels between ap-
proaches was equivalent. However silver stained gels did suggest
that proteins isolated by the automated workﬂow may be
marginally purer (Fig. 5). Any degree of improved puriﬁcation may
seem slight but it can have signiﬁcant effects on the success and
performance level of techniques like protein crystallography andNMR.
The principal motivation for this method development was to
reduce run times and there were some initial concerns that yields
would be reduced as a result of incomplete sample application or
peak collection. Indeed, in order to minimize sample volumes for
subsequent steps, and to avoid the collection of small unwanted
peaks, the criteria for peak recognition was tightly speciﬁed in the
software with relatively strict requirements in terms of both peak
height and slope. However, our early concerns about reduced yields
did not seem to materialize, with automated processing invariably
producing higher yields than the manual equivalent. It would
appear that any losses incurred as a result of strict peak recognition
in automation were less than losses observed by manual collection
and reformatting of intermediate products.
While others have described the use of multidimensional
chromatography for protein puriﬁcation there is less precedent for
the incorporation of protein conditioning and modiﬁcation steps.
By attaching a reservoir to a loop valve the method was able to
deliver appropriate reagents to puriﬁed proteins and achieve a
complete exchange of GDP to selected nucleotide analogues. Buffer
chase steps were included to push the complete volume of ex-
change reagents beyond the outlet valve and into the waiting
protein sample. A comprehensive recording of tubing and compo-
nent dead volumes and precise chasing of the reaction reagents
with buffer allowed us to conﬁdently deliver accurate triple digit
microliter volumes to intermediate proteins. This component has
the potential to automate a broad range of protein conditioning
events including co-factor delivery, chemical modiﬁcation, and the
introduction of other proteins for complex formation or the de-
livery of enzymes to manipulate post-translational modiﬁcations.
By far the main advantage offered by automated puriﬁcation is
reduced run time, with a three protein parallel GTPase puriﬁcations
taking approximately 44 h in contrast to the 96 h run time of the
manual workﬂow (Fig. 9). Indeed the run time can be compressed
further when producing proteins with compatible buffer
Fig. 8. KRas/SOS1 nucleotide exchange assay. (A) Equimolar concentrations of KRas 1e169 loaded with mantGDP by both production methods methods and applied to SOS1
catalysed nucleotide exchange which measures a quenching of mant ﬂuorescence when it is displaced from KRas by GTPgS. (B) The mean rates of exchange kinetics of both
preparations were almost identical (automated, 1.15 ± 0.032  103 sec1; manual 1.20 ± 0.010  103 sec1) demonstrating that the multidimensionally prepared mantGDP loaded
KRas was suitable for downstream applications. Data was analyzed and the rates derived by ﬁtting to a single exponential decay equation. The red line joining the data illustrates the
ﬁt. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 9. Run times for puriﬁcations by manual and automated workﬂows. Recording of puriﬁcation periods during both automated and manual workﬂows reveal substantial
compression of run times using the automated method with 50% reductions in duration in both single protein and three protein parallel productions.
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SEC columns, and then all parallel proteins can be repeatedly
applied without re-equilibration between sample injections. This
signiﬁcantly reduces the run time - in these circumstances parallel
puriﬁcation of GTPases by the method described would be further
reduced to only 31 h and 20 min. If it were practical to keep this
system supplied with lysates when required, each FPLC could
theoretically establish a throughput of 5 parallel multidimensional
runs per week and an output of 15 puriﬁed, activated GTPases.
Although this ideal is difﬁcult to achieve, the methodology has
greatly increased our ability to respond quickly to increases in
demand while maintaining or even enhancing the yield and quality
of the product. It is especially satisfying that it is now possible to
incorporate a sensitive reaction, like GTPase nucleotide exchange
Both incorporation of GMPPnP and mantGDP demonstrated quality
and performance consistent with KRas produced manually by
either HPLC nucleotide analysis or ﬂuorescent exchange assay
(Figs. 7 and 8).
In summary, the implementation of parallel multidimensional
workﬂows, even for relatively complex production protocols, offers
busy protein production teams the opportunity to increase routine
output, improve product quality and free up human resource for
other tasks thus loosening the bottleneck and accelerating the
discovery process.
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